Month: March 2023
Atorvastatin Reduced Left Ventricular Dysfunction From Anthracyclines: The STOP-CA Trial
Key Points
-Anthracycline therapy is associated with the development of heart failure, yet anthracyclines are among the most widely used and most effective antineoplastics.
-Limiting the cumulative dose of anthracycline, when possible, and screening for cardiotoxicity with echocardiograms should be standard practice.
-In the STOP-CA study, in patients with lymphoma treated with anthracyclines, the prophylactic use of atorvastatin over 12 months was associated with a lower rate of left ventricular dysfunction compared to placebo.
CLEAR Outcomes – Bempedoic Acid reduces Cardiovascular Events among Statin-Intolerant Patients
Key Points
Bempedoic acid, an ATP citrate lyase inhibitor, has been shown to reduce LDL cholesterol concentrations by 17% to 28% in clinical trials. However, data on whether bempedoic acid reduces cardiovascular events has been lacking.
The CLEAR Outcomes trial enrolled 13,970 statin-intolerant individuals at risk for, or with established cardiovascular disease, and randomized them to 180 mg of bempedoic acid per day or placebo.
Over a median follow-up of 40.6 months, treatment with bempedoic acid resulted in a 13% relative reduction in the composite primary endpoint of CV death, non-fatal myocardial infarction, non-fatal stroke, or coronary revascularization).
